Other Information.
−Removed: On September 7, 2023 , Vincent Capponi , the Company's President and Chief Operating Officer , adopted a 10b5-1 Trading Plan .
−Removed: providing for the sale of up to 62,700 shares of the Company's common stock during the period commencing on January 2, 2024 and concluding on March 28, 2024 .
−Removed: The Company had commenced a confidential marketing process for an underwritten public offering of its common stock and has decided to terminate such process.
−Removed: The termination resulted from an assessment by the Company’s Board of Directors and management team that current market conditions were not conducive for the offering on terms that would be in the best interests of the Company’s stockholders.
−Removed: The Company continues to pursue alternative sources of capital, which may include debt financing, royalty financing, strategic or direct investments, equity financing and/or combinations thereof.
−Removed: Employment Agreement, dated September 18, 2023, by and between the Company and Ms.
−Removed: Kathleen Bloch** (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on September 19, 2023).
Certification of Principal Executive Officer pursuant to 18 U.S.C.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
−Removed: Certification of Principal Financial Officer pursuant to 18 U.S.C.
+Added: Certification of Principal Interim Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
−Removed: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Consolidated Balance Sheets at September 30, 2023 and December 31, 2022, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 and (v) Notes to Consolidated Financial Statements.
+Added: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Consolidated Balance Sheets at March 31, 2024 and December 31, 2023, (ii) Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 and (v) Notes to Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
3 unchanged sentences
CYTOSORBENTS CORPORATION
−Removed: November 9, 2023
/s/ Phillip P.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 9, 2023
/s/ Kathleen P.
−Removed: Title:Chief Financial Officer
+Added: Interim Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.